Recently, the GLP-1 RA semaglutide was reported to reduce cardiovascular events in ASCVD patients with overweight or obesity even in the absence of diabetes mellitus
For instance, Sanofi in collaboration with HanmiPharm.Co.,Ltd are developing efpeglenatide, a GLP-1 receptor agonist for type 2 diabetes and obesity.It is currently undergoing phase-3study
[PMID: 8763856] PubMed record related to this compound for laboratory literature review
So basically, the ones that ended up quitting fasting were ones that were anticipating being hungry and would eat more, like an anticipation
However, it is important to note that whilst these mechanisms are promising, the specific application to binge eating disorder requires careful clinical evaluation, as this condition involves complex psychological, behavioural, and biological factors that extend beyond appetite regulation alone
General clinical guidelines recommend 2538 grams of fiber per day for most adults, though individual needs vary